ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
30 Dec 2022 10:38

Hong Kong Buybacks Weekly (Dec 30th): Tencent, AIA, Productive Technologies

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
686 Views
Share
23 Dec 2022 16:10

Hong Kong Buybacks Weekly (Dec 23rd): Tencent, AIA, GWM

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
626 Views
Share
18 Dec 2022 10:00

HK Short Interest Weekly: Tencent, Ping An H&T, Xiaomi, Jiumaojiu, Wuxi Biologics, XPeng

We analyzed the latest HK SFC report for aggregate short position as of Dec 9th and highlight short interest changes in Tencent, Ping An H&T,...

Logo
613 Views
Share
16 Dec 2022 11:23

Hong Kong Buybacks Weekly (Dec 16th): Tencent, AIA, Great Wall Motor

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
650 Views
Share
11 Dec 2022 11:30

Hong Kong Buybacks Weekly (Dec 9th):  Tencent, AIA, PetroChina

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
346 Views
Share
x